Dan Stanton, Managing editor

March 31, 2022

1 Min Read
Vetter and Rentschler double down on CDMO collaboration
Image: Stock Photo Secrets

Having originally teamed up in 2020, the two CDMOs have rebranded their combined drug substance and fill/finish service offering under the ‘Xpert Alliance’ umbrella.

The German contract development and manufacturing organizations (CDMOs) formed a strategic alliance in July 2020 to offer customers Rentschler’s drug substance manufacturing capacity in combination with Vetter’s aseptic fill and finish and secondary packaging services.

Nearly two years on, and the partnership has been formalized further through the creation of the ‘Xpert Alliance’ brand; a “visualization that aims to ‘bring to life’ our strong and ongoing strategic collaboration,” according to Vetter spokesperson Markus Kirchner.

jigsaw-300x180.jpg

Image: Stock Photo Secrets

Since 2020, the two independent companies have worked closely together to advance the collaboration and this week’s announcement “marks an important step in heightening the visibility of the collaborative services to clients, as the strategic alliance matures.”

He told BioProcess Insider: “The two CDMOs are mutually enhancing their services by offering complementary skills and experience along the biopharmaceutical value chain. Continuous improvement of alignment and process optimization has happened since the beginning of the collaboration.”

According to Kirchner, the two CDMOs have joint client projects at an advanced stage but are not able to outline any concrete numbers due to client confidentiality reasons.

“Both companies have known each other for many years and share a commitment to high quality standards and sustainable value creation. We are exploring ways to build on each other’s service portfolio by focusing on complimentary skills and experience along the biopharmaceutical value chain.”

When asked, Kirchner said this arrangement is not a steppingstone towards a future merger. “The companies remain independent and there is no obligation for clients to work with both companies.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.


Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.


From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like